Budget impact analysis of breast cancer in the Russian Federation
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2016, Vol 9, Issue 1
Abstract
Breast cancer is one of the leading causes of cancer-related morbidity and mortality in the female population of the Russia and its incidence is rapidly growing. Advanced breast cancer is a disease currently intreatable, but up-to-date management strategies result in significant improvement of symptoms, life expectancy and quality of life. Implementation of new technologies always results in extended healthcare expenditures, therefore requiring pharmacoeconomical justification. Russian Society for Pharmacoeconomics and Outcomes Research performed health economics evaluation of typical management strategies of patients with advanced hormone-dependent HER2-negative breast cancer, based on survey of experts. The questionnaire developed for this purpose including data relevant to epidemiological and pharmacoeconomic assessment of management of such patients. Calculation of expenses incurred by medications and medical care was performed based on experts’ data and according to the medical care standard #612н. Markov model in Microsoft Excel® application, as developed by York Health Economics Consortium, was used for pharmacoeconomic analysis. The model was based on approaches to treating patients with breast cancer for the duration of 5 years. Managing postmenopausal patients diagnosed with advanced hormone-dependent HER2-negative breast cancer with and without administration everolimus were assessed as alternative approaches, and the method of health economic analysis of budget impact was used to compare them. According to the analysis results, implementation of everolimus administration in the treatment strategies for postmenopausal patients with advanced hormone-dependent HER2-negative breast cancer does not incur significant increases of healthcare budget expenses in the Russian Federation.
Authors and Affiliations
Pavel Vorobiev, Liubov Krasnova, Malwina Hołownia
Keywords
Related Articles
- EP ID EP192259
- DOI 10.7365/JHPOR.2016.1.5
- Views 91
- Downloads 0
Cost-utility analysis and budget impact analysis of pegvisomant for the treatment of adult patients with acromegaly in Poland
Background: The aim of this publication was to evaluate the cost-effectiveness and financial consequences of pegvisomant (PEG) in the treatment of adult patients with acromegaly, who have had an inadequate response to su...
Assessment of thrombocytopenia symptoms using vignettes. Preliminary report on the development and implementation of a new instrument
Objective: Our aim was to create a vignette enabling the assessment of the impact of thrombocytopenia symptoms on patients’ quality of life. Methods: The vignettes which we created are focused on thrombocytopenia sym...
Assessment of quality and clinical significance of endpoints in cancer immunotherapy
This review describes available immunotherapeutic agents approved for the treatment of prostate cancer (sipuleucel-T), advanced melanoma (ipilimumab, pembrolizumab, nivolumab) and NSCLC (nivoluamb) and underline that the...
Cost-effectiveness study of diagnosis strategies of acute viral infections in Ukraine
Background: Efficient and accurate laboratory diagnosis of viral pathogens is of primary importance for clinical care in terms of health care system reforms. The methodological approach of cost-effectiveness analysis of...
Assessment of quality of life, disease activity and productivity loss of patients with ulcerative colitis in Poland
Purpose: The aim of the study was to assess the relationship between the disease activity and both indirect costs and health-related quality of life among ulcerative colitis (UC) patients in Poland. Methods: A questionn...